Synthetic agonists of FPR2 also protect the airway from inflammation. WKYMVm blocks DC migration to the mucosa and adjacent lymph nodes and inhibits proinflammatory cytokine production, which results in a decrease in Th1 and Th17 responses in asthma69. BML-111, another synthetic agonist of FPR2, has a therapeutic effect on ventilator-induced lung injury and lung injury induced by fat embolism syndrome. This compound inhibits leukocyte migration into BALF, production of proinflammatory cytokines, and NF-κB activation59,61.